title: [Determining serum concentrations of the modern antipsychotic quetiapin: clinical relevance in therapeutic drug monitoring].
abstract: OBJECTIVE
  The results concerning therapeutic drug monitoring of Quetiapin concentration in 152 in-patients will be presented.
  
  
  METHODS
  In addition to measuring the serum concentration of Quetiapin standardized patient data were collected and the clinical history assessed by the Brief Psychiatric Rating Scale (BPRS).
  
  
  RESULTS
  A significant positive correlation of the serum concentration and the daily dosage was found. Co-medication with the CYP 3A4 inhibitor Nefazodon was associated with an increase in the serum concentration without any adverse interactions occurring.
  
  
  CONCLUSIONS
  While a correlation of dosage and effect could be shown with Quetiapin, inter- and intraindividual differences could be observed. Drug monitoring therefore seems useful in clinical setting and is recommended.
authors.affiliation: Bezirkskrankenhaus Augsburg. oliver.koehnlein@bkh-augsburg.de
authors.forename: Oliver
authors.initials: O
authors.lastname: Köhnlein
authors.forename: Rita
authors.initials: R
authors.lastname: Lutz
authors.forename: Max
authors.initials: M
authors.lastname: Schmauss
authors.forename: Thomas
authors.initials: T
authors.lastname: Messer
mesh_terms: D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D010054:Brief Psychiatric Rating Scale; D051544:Cytochrome P-450 CYP3A; D065607:Cytochrome P-450 Enzyme Inhibitors; D003987:Dibenzothiazepines / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D016903:Drug Monitoring; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines; D011618:Psychotic Disorders / Q000097:blood* / Q000188:drug therapy; D000069348:Quetiapine Fumarate; D013223:Statistics as Topic; D014230:Triazoles / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D014150:Antipsychotic Agents; D065607:Cytochrome P-450 Enzyme Inhibitors; D003987:Dibenzothiazepines; D010879:Piperazines; D014230:Triazoles; D000069348:Quetiapine Fumarate; C051752:nefazodone; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A